AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
Follow ABBV
Alert me
AbbVie Inc. 10-Q filed May 8, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 4, 2025: 13 added · 33 removed · 35 modified; 12 with only figures updated
-
Modified
The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of
September 30March 31,20252026 and December 31,20242025 and the results of operations for the threeand ninemonths endedSeptember 30March 31,20252026 and20242025. This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, “Financial Statements and Supplementary Data.”